- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cannabis Weekly Round-Up: Canopy Gets Booted from S&P/TSX 60 Index
One of Canada's big-name cannabis producers no longer qualifies for a benchmark stock index, a sign of the decline in value the overall industry has seen.
Shares of Canopy Growth (NASDAQ:CGC,TSX:WEED) were dropped from a benchmark index in Canada, reflecting the company's poor performance in the stock market.
Also this week, a beverage manufacturer that plans to bet heavily on the cannabis industry began to set the stage for its entry with its most recent quarterly report.
Keep reading to find out more cannabis highlights from the past five days.
S&P/TSX 60 Index takes WEED off the list
One of the biggest cannabis companies in Canada was removed this past week from the S&P/TSX 60 Index (INDEXTSI:TX60), which contains large-cap companies in the Canadian equities market.
The move comes as part of a scheduled quarterly review from the overseer of the index, S&P Dow Jones Indices
Canopy was originally added to the index in April 2019. At the time, the company called the addition a “major accomplishment." Since then, Canopy shares have declined in value by nearly 90 percent. The company was trading at C$56.31 when it was first added, and was at just C$8.18 as of this Thursday's (March 10) close.
Jones Soda nears launch of cannabis beverage business
On Thursday, soda maker Jones Soda (CSE:JSDA,OTCQB:JSDA) released its Q4 and full 2021 results.
Jones Soda is pursuing the development of THC- and CBD-infused beverages, and plans to leverage its drink-making experience and promotion of novel beverages. As part of its report, the firm indicates that it incurred US$0.4 million in cannabis-related business expenses as it sets up for its official launch.
“Additionally, we are planning to launch our cannabis portfolio by the end of Q1 and expect it will be an immediate hit with consumers as we leverage the strength and community of the Jones Soda brand,” Mark Murray, president and CEO of Jones Soda, said in a statement.
The firm recently listed its shares on the Canadian Securities Exchange in alignment with its cannabis intentions and as a way to “increase the liquidity of our shares and appeal to a broader investor base.”
Jones Soda reported a net loss for the Q4 period of US$1.3 million, which the firm said was due to its cannabis business expenses. For the year, the company reported a US$1.8 million net loss, an improvement from the US$3 million reported during the previous period.
Shares of the company have jumped since releasing its financial report. As of 10:50 a.m. EST on Friday (March 11), Jones Soda was up 21.43 percent in value for a price point of C$0.85 per share in Canada.
Cannabis company news
- Acreage Holdings (CSE:ACRG.A.U,OTCQX ACRHF)issued its Q4 and full-year financial results for investors. The company reported a net loss of US$35.6 million for the quarter and US$47 million for all of 2021. Revenue for the company jumped 65 percent for the entire year to reach a line of US$188.9 million. “We have accomplished many key priorities in a short period and are well-positioned to build on this momentum throughout 2022,” Acreage CEO Peter Caldini said.
- Tetra Bio-Pharma (TSX:TBP,OTCQB:TBPMF)received Health Canada approval for a proposed amendment of a Phase I study on the cognitive, behavioral and biological effects of CBD on adults.
- TerrAscend (CSE:TER,OTCQX:TRSSF)completed its acquisition of Gage Growth (CSE:GAGE,OTCQX:GAEGF). "I believe the combination of TerrAscend and Gage has created one of the most compelling and differentiated operators in the North American cannabis industry," Jason Wild, executive chairman of TerrAscend, said.
- Village Farms International (NASDAQ:VFF)announced its cannabis producer subsidiary Pure Sunfarms secured an official EU GMP certification from the District Government of Dusseldorf, Germany. The approval was given to the producer’s facility in Delta, BC. "In addition to the expected near-term growth from this expansion, we believe existing medical markets in the EU, and elsewhere, are a pathway to participating in much larger legal recreational cannabis opportunities as these markets develop," President and CEO Michael A. DeGiglio said.
Don't forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.
Learn about our editorial policies.